Understanding the Challenges of Chronic Diseases in Indonesia

Oct 13, 2025 by pynkocean.com 45 views

Understanding the Challenges of Chronic Diseases in Indonesia

Chronic diseases, such as hypertension, diabetes, and coronary heart disease, are one of the biggest challenges in the health system in Indonesia. These diseases not only affect the quality of life of patients but also impose a significant financial burden on patients, hospitals, and social security organizing agencies (BPJS Health). The financial load caused by treatment of these diseases, especially drug costs, can be a significant problem for patients, hospitals, and social security organizing agencies. Therefore, analysis of drug claims for chronic diseases is very important to understand the pattern of drug use and optimize cost management.

Research Purpose and Significance

This study aims to analyze chronic drug claims for BPJS patients at Prof. Dr. Chairuddin Panusunan Lubis Medan (RSP CPL Medan). Through this study, it is expected to provide insight into drug expenditure related to chronic diseases and help the hospital and BPJS in the planning and management of health costs. The study will also help to identify the factors that affect the cost of chronic disease drugs and provide recommendations for optimizing the use of drugs and managing costs.

Methodology and Data Collection

This study uses a quantitative descriptive approach with retrospective observational study design. BPJS patient drug claim data at RSP CPL Medan is collected from medical records and drug use data in pharmaceutical installations during the April to June 2023 period. For sampling, a probability method with proportional stratified random sampling is used. The data collected is then grouped based on inclusion criteria, then analyzed using Statistical Product and Service Solution (SPSS) software version 22 and Microsoft Excel. Data analysis was carried out using the Kruskal-Wallis test and Mann-Whitney test.

Research Result and Findings

From the results of the analysis, found a significant difference between the number of prescribed drugs and differences in the cost of chronic disease drugs for BPJS patients. It is known that the more drugs are prescribed, the higher the difference in cost. In addition, there is a significant difference between the type of polyclinic and the difference in the cost of chronic diseases for BPJS patients, which shows a variety of drug costs in various polyclinics. However, no significant differences were found between the number of secondary diagnoses and differences in the cost of chronic diseases for BPJS patients.

Analysis and Implications of the Study

This finding highlights the importance of understanding the factors that affect the cost of chronic disease drugs. Variability on the cost of drugs between polyclinics shows that policies in each polyclinic may differ in the management of recipes and expenses. Therefore, hospitals need to evaluate treatment policies and cost management in order to provide more efficient and economical services for patients.

In terms of BPJS Health, the results of this study can be used as a basis for formulating strategies in managing claims and cost control. Monitoring of drug use patterns and related costs can help prevent waste and ensure that patients get optimal treatment.

Conclusion and Recommendations

This study shows that several factors affect differences in the cost of chronic disease drugs for BPJS patients at RSP CPL Medan, including the number of prescribed drugs and polyclinic types. Further efforts are needed in optimizing the use of drugs and managing costs so that the health system in Indonesia can run more effectively and sustainably. Through a better understanding of this drug claim pattern, it is expected to improve the quality of health services for the whole community.

Limitations of the Study

This study has several limitations. Firstly, the study only focuses on BPJS patients at RSP CPL Medan, which may not be representative of all patients with chronic diseases in Indonesia. Secondly, the study only analyzes the cost of chronic disease drugs and does not consider other factors that may affect the cost of treatment, such as the cost of hospitalization and other medical expenses.

Future Research Directions

Future research should focus on identifying the factors that affect the cost of chronic disease treatment beyond the cost of drugs. This may include analyzing the cost of hospitalization, other medical expenses, and the impact of treatment policies on the cost of care. Additionally, future research should focus on developing strategies to optimize the use of drugs and manage costs in the health system in Indonesia.

Implications for Policy and Practice

The findings of this study have several implications for policy and practice. Firstly, hospitals need to evaluate treatment policies and cost management in order to provide more efficient and economical services for patients. Secondly, BPJS Health needs to formulate strategies in managing claims and cost control, including monitoring of drug use patterns and related costs. Finally, the government needs to develop policies to support the health system in Indonesia, including increasing funding for healthcare and improving the quality of healthcare services.

Conclusion

In conclusion, this study provides valuable insights into the pattern of drug use and cost management for chronic diseases in Indonesia. The study highlights the importance of understanding the factors that affect the cost of chronic disease drugs and provides recommendations for optimizing the use of drugs and managing costs. The study also has several limitations and future research directions, including identifying the factors that affect the cost of chronic disease treatment beyond the cost of drugs and developing strategies to optimize the use of drugs and manage costs in the health system in Indonesia.

Q: What is the main objective of this study?

A: The main objective of this study is to analyze chronic drug claims for BPJS patients at Prof. Dr. Chairuddin Panusunan Lubis Medan (RSP CPL Medan) and provide insight into drug expenditure related to chronic diseases.

Q: What is the methodology used in this study?

A: This study uses a quantitative descriptive approach with retrospective observational study design. BPJS patient drug claim data at RSP CPL Medan is collected from medical records and drug use data in pharmaceutical installations during the April to June 2023 period.

Q: What are the findings of this study?

A: The study found a significant difference between the number of prescribed drugs and differences in the cost of chronic disease drugs for BPJS patients. It is also found that there is a significant difference between the type of polyclinic and the difference in the cost of chronic diseases for BPJS patients.

Q: What are the implications of this study?

A: The study highlights the importance of understanding the factors that affect the cost of chronic disease drugs. Variability on the cost of drugs between polyclinics shows that policies in each polyclinic may differ in the management of recipes and expenses.

Q: What are the limitations of this study?

A: This study has several limitations. Firstly, the study only focuses on BPJS patients at RSP CPL Medan, which may not be representative of all patients with chronic diseases in Indonesia. Secondly, the study only analyzes the cost of chronic disease drugs and does not consider other factors that may affect the cost of treatment.

Q: What are the future research directions?

A: Future research should focus on identifying the factors that affect the cost of chronic disease treatment beyond the cost of drugs. This may include analyzing the cost of hospitalization, other medical expenses, and the impact of treatment policies on the cost of care.

Q: What are the implications for policy and practice?

A: The findings of this study have several implications for policy and practice. Firstly, hospitals need to evaluate treatment policies and cost management in order to provide more efficient and economical services for patients. Secondly, BPJS Health needs to formulate strategies in managing claims and cost control, including monitoring of drug use patterns and related costs.

Q: What is the conclusion of this study?

A: In conclusion, this study provides valuable insights into the pattern of drug use and cost management for chronic diseases in Indonesia. The study highlights the importance of understanding the factors that affect the cost of chronic disease drugs and provides recommendations for optimizing the use of drugs and managing costs.

Q: What are the recommendations for healthcare providers?

A: The study recommends that healthcare providers should evaluate treatment policies and cost management in order to provide more efficient and economical services for patients. They should also monitor drug use patterns and related costs to prevent waste and ensure that patients get optimal treatment.

Q: What are the recommendations for BPJS Health?

A: The study recommends that BPJS Health should formulate strategies in managing claims and cost control, including monitoring of drug use patterns and related costs. They should also develop policies to support the health system in Indonesia, including increasing funding for healthcare and improving the quality of healthcare services.

Q: What are the recommendations for the government?

A: The study recommends that the government should develop policies to support the health system in Indonesia, including increasing funding for healthcare and improving the quality of healthcare services. They should also monitor the implementation of healthcare policies and programs to ensure that they are effective and efficient.